TY - JOUR
T1 - Cost-benefit and cost-effectiveness
T2 - methodologies for evaluating innovative pharmaceutical services.
AU - McGhan, W. F.
AU - Rowland, C. R.
AU - Bootman, J. L.
PY - 1978/2
Y1 - 1978/2
N2 - Cost-benefit and cost-effectiveness analysis techniques which can be of assistance in the evaluation of innovative pharmaceutical services are reviewed. Process and outcome measures are considered, and suggested steps in a cost-benefit study are presented. Samples of pharmacy studies using these techniques are appraised. Possible measures for benefits and costs along with literature references for evaluations of innovative pharmaceutical services are presented. Areas of pharmaceutical service discussed are ambulatory patient consultation, unit dose drug distribution, drug information services, monitoring drug therapy in acute care and long-term care, parenteral admixture services, patient and therapy responsibilities, patient discharge interviews, patient drug histories and profiles, and personnel substitutions. Although there have been several encouraging reports on the cost-benefit of pharmaceutical services, more evaluative research is needed to develop programs which maximize the benefit-to-cost ratio to society.
AB - Cost-benefit and cost-effectiveness analysis techniques which can be of assistance in the evaluation of innovative pharmaceutical services are reviewed. Process and outcome measures are considered, and suggested steps in a cost-benefit study are presented. Samples of pharmacy studies using these techniques are appraised. Possible measures for benefits and costs along with literature references for evaluations of innovative pharmaceutical services are presented. Areas of pharmaceutical service discussed are ambulatory patient consultation, unit dose drug distribution, drug information services, monitoring drug therapy in acute care and long-term care, parenteral admixture services, patient and therapy responsibilities, patient discharge interviews, patient drug histories and profiles, and personnel substitutions. Although there have been several encouraging reports on the cost-benefit of pharmaceutical services, more evaluative research is needed to develop programs which maximize the benefit-to-cost ratio to society.
UR - https://www.scopus.com/pages/publications/0017933616
UR - https://www.scopus.com/inward/citedby.url?scp=0017933616&partnerID=8YFLogxK
M3 - Review article
C2 - 415603
AN - SCOPUS:0017933616
SN - 0002-9289
VL - 35
SP - 133
EP - 140
JO - American Journal of Hospital Pharmacy
JF - American Journal of Hospital Pharmacy
IS - 2
ER -